GlassScriptPhysician profile
Rogelio Suarez
NPI 1932514965
$16,361.42
in general payments reported to CMS, 2019-2025
26 companies · $3,261 in 2025
The $3,261 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,651 · 2020: $1,358 · 2021: $1,559 · 2022: $2,216 · 2023: $2,942 · 2024: $3,373 · 2025: $3,261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,527 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,527.20 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $2,181.33 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $1,978.73 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,776.11 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $1,529.61 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $1,506.15 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Alkermes, INC. | $1,372.10 | 2019-2025 | Aristada, Lybalvi |
| Allergan, INC. | $959.83 | 2019-2020 | |
| Lundbeck LLC | $828.71 | 2019-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $808.62 | 2019-2025 | Fanapt, Hetlioz |
| Indivior INC. | $713.85 | 2020-2024 | Perseris |
| E.R. Squibb & Sons, L.L.C. | $693.66 | 2024-2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $509.38 | 2022-2025 | Quviviq, Quviviq |
| Axsome Therapeutics, INC. | $465.02 | 2022-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $264.85 | 2020-2023 | Trintellix |
| Bausch Health US, LLC | $212.37 | 2022-2025 | Aplenzin |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $147.08 | 2021-2024 | Ingrezza |
| Almatica Pharma LLC | $142.77 | 2023-2025 | Loreev Xr |
| Luye Pharma (USA) LTD. | $76.14 | 2025 | Erzofri Extended-Release |
| Acadia Pharmaceuticals INC | $63.99 | 2022-2023 | Nuplazid |
| Tempus Ai, INC | $29.35 | 2024 | |
| Merck Sharp & Dohme LLC | $26.86 | 2022-2023 | Belsomra |
| Eisai INC. | $17.14 | 2020 | |
| Shire North American Group INC | $16.23 | 2019 | |
| Noven Therapeutics, LLC | $15.39 | 2024 | Secuado, Xelstrym |
| Penumbra, INC. | $14.86 | 2023 | Penumbra System |
| Adlon Therapeutics L.P. | $11.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rogelio Suarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.